|
Synairgen positive on asthma study latest
Stock Market Wire StockMarketWire.com – Synairgen plc, the respiratory drug discovery and development company with a particular focus on viral defence of the lungs, has provided an update on its Phase II asthma study. The company has announced that the outcome of the … |
View full post on asthma – Google News